Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1. RAS as an oncogene

2. The undruggable RAS

3. KRAS G12C as a specific exception

4. Daroxonrasib as a pan RAS(On) inhibitor

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Wang-Gillam A , et al. Eur J Cancer. 2019;108:78-87. doi:10.1016/j.ejca.2018.12.007

2.           O’Reilly EM  et al. N Engl J Med. Published online May 31, 2026. doi:10.1056/NEJMOA2605555

3.           Cregg J et al. J Med Chem. 2025;68(6):6041-6063. doi:10.1021/ACS.JMEDCHEM.4C02313/

4.           Fakih MG et al.  Engl J Med. 2023;389(23):2125-2139. doi:10.1056/NEJMOA2308795

5.           de Langen AJ, et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0

6.           Cox AD et al. Nat Rev Drug Discovery 2014 13:11. 2014;13(11):828-851. doi:10.1038/nrd4389

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

1. Nomenclature, unique considerations

2. Secretory Syndromes

3. Somatostatin directed therapy

4. Peptide Receptor Radionucleotide Therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1–10

1.   Kunz PL  et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/

2.  Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6

3.  Strosberg J  et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427/

4.  Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158/

5.   Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-6.  Neuroendocrine Tumor Guidelines, ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers

7.   Pieterman CRC  , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468

8.   NANETS. Accessed May 1, 2025. https://nanets.net/

9.  Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612,

10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510,

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Etiologies and epidemiology
2. Staging and local/regional considerations
3. Systemic Therapy
4. Differences in immune checkpoint sensitivity by etiology

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183

2.           Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0

3.           Zhu AX  et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9

4.           Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070

5.           Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1

7.           Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857

8.           Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018

9.           Cheng AL et al.  J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030

10.        Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/

11.        Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

 1. Stage II Disease
2. Overview of BEP, EP, VIP
3. Advanced, refractory disease
4. Survivorship considerations

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.          Pico JL et al. Ann Oncol. 2005;16(7):1152-1159. doi:10.1093/ANNONC/MDI228

2.          Adra N, et al. J Clin Oncol. 2017;35(10):1096-1102. doi:10.1200/JCO.2016.69.5395

3.          Nichols CR et al. J Clin Oncol. 1998;16(4):1287-1293. doi:10.1200/JCO.1998.16.4.1287

4.          de Wit R et al.. JCO. 1997;15(5):1837-1843. doi:10.1200/JCO.1997.15.5.1837

5.          Culine S, et al.  Ann Oncol. 2007;18(5):917-924. doi:10.1093/ANNONC/MDM062

6.          Lorch A, et al. Journal of Clinical Oncology. 2007;25(18_suppl):5086-5086. doi:10.1200/JCO.2007.25.18_SUPPL.5086

7.          Fung C, et al.. J Natl Compr Canc Netw. 2019;17(12):1557-1568. doi:10.6004/JNCCN.2019.7369

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Background, work up
2. Staging of seminoma and NSGCT
3. Young Adult/Adolescent Oncology
4. Management of Stage I Disease

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.          Hiester A et al. Eur J Cancer. 2021;155:64-72. doi:10.1016/J.EJCA.2021.06.022

2.          Calaway AC et al. Eur Urol. 2019;76(5):607-609. doi:10.1016/j.eururo.2019.05.031

3.          Oliver RTD et al. J Clin Oncol. 2011;29(8):957-962. doi:10.1200/JCO.2009.26.4655

4.          Oliver RTD et al. Lancet. 2005;366(9482):293-300. doi:10.1016/S0140-6736(05)66984-X

5.          Joffe JK et al. JCO. 2022;40(22):2468-2478. doi:10.1200/JCO.21.01199/

6.          Bhatia S et al.. J NCCN. 2023;21(8):851-880. doi:10.6004/JNCCN.2023.0040

7.          Stephenson A et al. J Urol. 2019;202(2):272-281. doi:10.1097/JU.0000000000000318

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Historical Approach (cytoreduction, IFN-a, sunitinib
2. Prognostic risk scores
3. Evidence for modern doublet regimens
4. Later line therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Flanigan RC et al.  J Urol.  2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae
2. Bex A et al. JAMA Oncology. 2019;5(2):164-170.  doi:10.1001/jamaoncol.2018.5545
3. Mejean A et al. NEJM.  2018;379:417-427. doi:10.1056/NEJMoa1803675
4. Motzer RJ et al.  NEJM.  2007;356:115-124. doi:10.1056/NEJMoa065044
5. Rini BI et al.  NEJM.  2019;380:1116-1127. doi:10.1056/NEJMoa1816714
6. Rini BI et al. JCO.  2023;41(17 Supp).  doi:10.1200/JCO.2023.41.17_suppl.LBA4501
7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023
8. Motzer RJ et al. NEJM. 2018;378:1277-1290.  doi:10.1056/NEJMoa1712126
9. Motzer R et al.  NEJM.  2021;384:1289-1300.  doi:10.1056/NEJMoa2035716
10. Albiges L et al.  Ann Oncol.  2023;34(2 Supp):S1329-S1330.  doi:10.1016/j.annonc.2023.10.090
11. Jonasch E.  ASCO Annual Meeting presented May 31, 2024 in Chicago, IL

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Risk Factors and Presentation
2. Staging and Paraneoplastic syndromes
3. Localized Therapy Options and Considerations
4. Evidence and Limitations for Adjuvant Systemic Therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology. 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG

2.           Ravaud A et al. NEJM. 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/

3.           Pal SK et al. Lancet. 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0

4.           Motzer RJ et al. Lancet. 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0

5.           Correa AF et al. Eur Urol. 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025

6.           Choueiri TK et al. NEJM. 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/

7.           Choueiri TK et al. NEJM. 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Immunohistochemistry of urothelial cancer
2. History of systemic therapy in advanced and metastatic disease
3. Pembrolizumab and Enfortumab Vedotin
4. Approach to second line therapy and beyond

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

 1.          Powles T et al.  NEJM. 2024;390(10):875-888. doi:10.1056/NEJMOA2312117/

2.          Powles T et al. NEJM. 2020;383(13):1218-1230. doi:10.1056/NEJMOA2002788/

3.          Galsky MD  et al. Lancet. 2020;395(10236):1547-1557. doi:10.1016/S0140-6736(20)30230-0

4.          Powles T et al. Lancet Oncol. 2021;22(7):931-945. doi:10.1016/S1470-2045(21)00152-2

5.          van der Heijden MS et al. NEJM. 2023;389(19):1778-1789. doi:10.1056/NEJMOA2309863/

6.          Von der Maase H et al. JCO. 2000;18(17):3068-3077. doi:10.1200/JCO.2000.18.17.3068/

7.          von der Maase H et al. JCO. 2023;41(23):3881-3890. doi:10.1200/JCO.22.02763

8.          Vuky J et al. . JCO. 2020;38(23):2658-2666. doi:10.1200/JCO.19.01213

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.  Etymology, presentation, and work-up of bladder/urothelial cancer
2. Role of perioperative systemic therapy
3. Tri-modality therapy (bladder sparing approach)
4. Considerations for upper tract urothelial cancer

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Bellmunt J et al. Lancet Oncol. 2021;22(4):525-537. doi:10.1016/S1470-2045(21)00004-8

2.           Birtle AJ et al. JCO. Published online February 13, 2024. doi:10.1200/JCO.23.01659

3.           Birtle A  et al. Lancet. 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3

4.           Bajorin DF et al. NEJM. 2021;384(22):2102-2114. doi:10.1056/NEJMOA2034442/

5.           James ND et al. NEJM. 2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106/

6.           Pfister C et al. JCO 2023;41(17_suppl) doi:10.1200/JCO.2023.41.17_SUPPL.LBA4507

7.           Pfister C et al. Eur Urol. 2021;79(2):214-221. doi:10.1016/J.EURURO.2020.08.024

8.           Grossman HB et al. NEJM. 2003;349(9):859-866. doi:10.1056/NEJMOA022148/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.   Clinical presentation and work-up
2. Intestinal and pancreatobiliary subtypes
3. Role of perioperative therapy
4. Considerations for metastatic disease

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

 1.           Neoptolemos JP et al. JAMA. 2010;304(10):1073-1081. doi:10.1001/JAMA.2010.1275

2.           Smeenk HG et al.. Ann Surg. 2007;246(5):734-740. doi:10.1097/SLA.0B013E318156EEF3

3.           Chang DK  , et al. J Clin Oncol. 2013;31(10):1348-1356. doi:10.1200/JCO.2012.46.8868

4.           Schueneman A et al. Br J Cancer. 2015;113(1):64-68. doi:10.1038/BJC.2015.172

5.           Chiorean EG et al. Journal of the National Comprehensive Cancer Network. 2023;21(7):753-782. doi:10.6004/JNCCN.2023.0034

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology